Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
Sponsor: Asian Institute of Gastroenterology, India
Summary
Primary Objective • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily. Secondary Objectives * To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.
Official title: Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
414
Start Date
2025-12-20
Completion Date
2027-12-12
Last Updated
2026-03-06
Healthy Volunteers
No
Conditions
Interventions
Vonoprazan
Vonaprazon is potassium competitive acid blockers
Esomeprazole 40mg
esomeprazole is a proton pump inhibitor as it prevents excess of gastric acid secretion in the stomach
Locations (1)
Asian Institute of Gastroenterology /Aig Hospitals
Hyderabad, Telangana, India